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5. Tools of the visualization
6. How to avoid the common mistakes in analyzing the data derived 
from the high throughput assays.
Targeted audience: Researchers, Molecular Biologist, Clinical Re-
search Scientist, R&D Professionals, IT & Informatics Professionals, 
Statisticians, Bioinformaticians, and mathematicians.
Talk outline: Many of the examples of this talk are based on actual mi-
croarray gene proﬁle data as well as the matrix assisted laser desorption 
ionization time-of-ﬂight, mass spectrometry (MALDI-TOF MS) protein 
proﬁle data that I have analyzed or recently published articles. My hope 
is that the theory of the bioinformatics aspects of the examples would 
provide a springboard for the motivated audience. The topics that will 
be covered in this talk are: 
1. Introduction to the high throughput assays - today and tomorrow.
2. Issues of the experiment design of the high throughput assays.
3. Topics of the data pre-processing including the assessment of the 
quality control.
4. Methods of the data analysis: data mining, pattern recognition, class 
comparison, model prediction.
5. Tools of the visualization
The common mistakes of analyzing the data derived from the high 
throughput assays will be discussed. Several software packages such as 
Wavelet-based Project Spectrum Network (WPSN) package for mass 
spectrum data preprocessing, Weighted Flexible Compound Covariate 
Method (WFCCM) for class prediction, and Mutidimensional Scaling 
and Cluster analysis for visualization will be introduced to the audi-
ence. The goal of this talk is understanding, applying, and not misusing 
the bioinformatics tools in high dimensional data derived from high 
throughput assays.
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Lung cancer is one of the leading causes of death globally. Over the 
past two decades, signiﬁcant advances have been made in the treatment 
of non-small cell lung cancer (NSCLC). Randomized phase III studies 
continue to be the gold standard for deﬁning new standard of care. 
Phase III trials are expensive, time consuming and resource intensive. 
A vast majority (>90%)of phase III trials do not meet their endpoints. 
While the number of new compounds registered for development in 
NSCLC is higher now than ever before, the proportion of adults with 
cancer enrolled in clinical trials is dismally low. There is an urgent need 
to develop novel phase II designs and endpoints that would enable us 
to select compounds /combinations that are likely to succeed in phase 
III trials.
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Pharmacogenomics is known as the science that allows researchers to 
predict the probability of a drug response based on a person’s genetic 
makeup. For instance, it is known that patients with Gilbert’s disease 
associated with UGT1A1 polymorphism will have excessive toxicity 
with the recommended dose of irinotecan due to impaired ability of 
detoxifying the active metabolite of the drug. On the label, “Individu-
als who are homozygous for the UGT1A*28 allele are at increased risk 
for neutropenia following initiation of irinotecan treatment. A reduced 
initial dose should be considered for patients known to be homozygous 
for the UGT1A*28 allele. Heterozygous patients may be at increased 
risk of neutropenia; however clinical results have been variable and 
such patients have been shown to tolerate normal starting doses. 
Although a large amount of new data on relationship between clinical 
outcome of current therapeutic strategies and interindividual genetic 
markers are being published, clinical efﬁcacy and toxicity for the 
individual patient of particular chemotherapy agents are unpredictable 
(Lenz HJ, JCO 2004;22:2519-2521). From the statistical viewpoints, 
we can say that the prediction from UGT1A1 polymorphism to inci-
dence of some toxicity is another issue.
We recently developed a prognostic index to discriminate the risk 
groups among advanced epithelial ovarian cancer based on demo-
graphic, clinical and pathological characteristics of patients (Teramukai 
S, et al. JCO 2007, in press). Accuracy of the simple risk group model 
was statistically evaluated with respect to discrimination and calibra-
tion and reproducibility of the model was accessed by data-splitting 
method. The deﬁnitions of accuracy and generalizability with regard 
to assessment of a prognostic system have been discussed (Justice 
AC, et al. Ann Intern Med 1993;130:515-524). Accuracy (calibration 
and discrimination) is the degree to which predictions match observed 
outcomes. Generalizability (reproducibility and transportability) is the 
ability of a prognostic system to provide accurate predictions in a new 
sample of patients. Reproducibility requires the system to replicate its 
accuracy in patients who were not included in development of the sys-
tem but who are from the same underlying population. Transportability 
requires the system to produce accurate predictions in a sample drawn 
from a different but plausibly related population or in data collected 
by using slightly different methods than those used in the development 
sample. A goal of personalized medicine is to improve such a partially 
validated prognostic system incorporating genomic information, to 
evaluate reproducibility with prospective clinical trials, and to assess 
generalizability with large-scale database on clinical practice.
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Introduction: Our immune system is our body’s natural defense 
mechanism and consists of two types of immune responses, innate vs 
adaptive. Although our immune system is effective in defending against 
infectious diseases, it appears ineffective in defending against a cancer 
once it has been established in the body. Two widely accepted reasons 
that manipulation of the immune system for cancer treatment has been 
unsuccessful are that cancer is not immunogenic and that the cancer 
microenvironment can suppress the immune system. The purpose of 
cancer vaccine or immunotherapy is to elicit a more powerful active 
immunity, either antibody-mediated or cell-mediated, from patients 
to overcome these two barriers to development of therapeutic cancer 
immunity.
